The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction: TIMI 11B–ESSENCE Meta-Analysis
Open accessAbstract
Background —Two phase III trials of enoxaparin for unstable angina/non–Q-wave myocardial infarction have shown it to be superior to unfractionated heparin for preventing a composite of death and cardiac ischemic events. A prospectively planned meta-analysis was performed to provide a more precise estimate of the effects of enoxaparin on multiple end points. Methods and Results —Event rates for death, the composite end points of death/nonfatal myocardial infarction and death/nonfatal myocardial infarction/urgent revascularization, and major hemorrhage were extracted from the TIMI 11B and ESSENCE databases. Treatment effects at days 2, 8, 14, and 43 were expressed as the OR (and 95% CI) for enoxaparin versus unfractionated heparin. All heterogeneity tests for efficacy end points were negative, which suggests comparability of the findings in TIMI 11B and ESSENCE. Enoxaparin was associated with a 20% reduction in death and serious cardiac ischemic events that appeared within the first few days of treatment, and this benefit was sustained through 43 days. Enoxaparin’s treatment benefit was not associated with an increase in major hemorrhage during the acute phase of therapy, but there was an increase in the rate of minor hemorrhage. Conclusions —The accumulated evidence, coupled with the simplicity of subcutaneous administration and elimination of the need for anticoagulation monitoring, indicates that enoxaparin should be considered as a replacement for unfractionated heparin as the antithrombin for the acute phase of management of patients with high-risk unstable angina/non–Q-wave myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Weitz, J. I. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371007 · Cited by 1,533
Cohen, M., Demers, C., Gurfinkel, E. P., Turpie, A. G. G., Fromell, G. J., Goodman, S., Langer, A., Califf, R. M., Fox, K. A. A., Premmereur, J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708143370702 · Cited by 1,424
Self-citationMethods in Observational Epidemiology
Kelsey, J. L. (1986) · Cited by 1,307
Aspirin, Heparin, or Both to Treat Acute Unstable Angina
Théroux, P., Ouimet, H., McCans, J., Latour, J.-G., Joly, P., Lévy, G., Pelletier, E., Juneau, M., Stasiak, J., deGuise, P., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810273191701 · Cited by 1,276
Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., & Chalmers, T. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207233270406 · Cited by 1,140
Self-citationAntman, E. M., McCabe, C. H., Gurfinkel, E. P., Turpie, A. G. G., Bernink, P. J. L. M., Salein, D., Bayes de Luna, A., Fox, K., Lablanche, J.-M., Radley, D., et al. (1999) · Circulation · doi:10.1161/01.cir.100.15.1593 · Cited by 1,052
Self-citationThe RISC Group (1990) · The Lancet · doi:10.1016/0140-6736(90)92336-g · Cited by 781
Simoons, M. L. (1996) · RePub (Erasmus University Rotterdam) · Cited by 706
Madden, C. (1991) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(05)81237-5 · Cited by 691
Low-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 685
A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
(1996) · New England Journal of Medicine · doi:10.1056/nejm199609123351103 · Cited by 660
Klein, W., Buchwald, A., Hillis, S. E., Monrad, S., Sanz, G., Turpie, A. G. G., van der Meer, J., Olaisson, E., Undeland, S., & Ludwig, K. (1997) · Circulation · doi:10.1161/01.cir.96.1.61 · Cited by 526
Antman, E. M. (1996) · Circulation · doi:10.1161/01.cir.94.5.911 · Cited by 485
Self-citationOler, A. (1996) · JAMA · doi:10.1001/jama.276.10.811 · Cited by 483
Robins, J., Breslow, N., & Greenland, S. (1986) · Biometrics · doi:10.2307/2531052 · Cited by 476
Reactivation of Unstable Angina after the Discontinuation of Heparin
Théroux, P., Waters, D., Lam, J., Juneau, M., & McCans, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207163270301 · Cited by 464
A comparison of statistical methods for combining event rates from clinical trials
Berlin, J. A., Laird, N. M., Sacks, H. S., & Chalmers, T. C. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080202 · Cited by 420
Diagnosing and managing unstable angina. Agency for Health Care Policy and Research.
Braunwald, E., Jones, R. H., Mark, D. B., Brown, J., Brown, L., Cheitlin, M. D., Concannon, C. A., Cowan, M., Edwards, C., & Fuster, V (1994) · Circulation · doi:10.1161/01.cir.90.1.613 · Cited by 418
Self-citationXiao, Z., & Théroux, P. (1998) · Circulation · doi:10.1161/01.cir.97.3.251 · Cited by 382
Cohen, M., Adams, P. C., Parry, G., Xiong, J., Chamberlain, D., Wieczorek, I., Fox, K. A., Chesebro, J. H., Strain, J., & Keller, C. (1994) · Circulation · doi:10.1161/01.cir.89.1.81 · Cited by 378
Self-citationLow-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)
Swahn, E., & Wallentin, L. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00486-4 · Cited by 354
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
Lane, D. A., Denton, J., Flynn, A. M., Thunberg, L., & Lindahl, U. (1984) · Biochemical Journal · doi:10.1042/bj2180725 · Cited by 342
Unstable angina : diagnosis and management
Braunwald, E. (1994) · Medical Entomology and Zoology · Cited by 332
Self-citationTelford, A., & Wilson, C. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92399-0 · Cited by 322
(1999) · The Lancet · doi:10.1016/s0140-6736(98)07332-2 · Cited by 322
Antithrombotic agents in coronary artery disease
Resnekov, L., Chediak, J., Hirsh, J., & Lewis, H. D. (1989) · Chest · doi:10.1378/chest.95.2.52s · Cited by 263
Montalescot, G., Philippe, F., Ankri, A., Vicaut, E., Bearez, E., Poulard, J. E., Carrie, D., Flammang, D., Dutoit, A., Carayon, A., et al. (1998) · Circulation · doi:10.1161/01.cir.98.4.294 · Cited by 250
The Mode of Action of Heparin in Plasma
Béguin, S., Lindhout, T., & Hemker, H. C. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646990 · Cited by 230
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
Hirsh, J., & Fuster, V (1994) · Circulation · doi:10.1161/01.cir.89.3.1449 · Cited by 222
Mark, D. B., Cowper, P. A., Berkowitz, S. D., Davidson-Ray, L., DeLong, E. R., Turpie, A. G. G., Califf, R. M., Weatherley, B., & Cohen, M. (1998) · Circulation · doi:10.1161/01.cir.97.17.1702 · Cited by 171
Self-citationBias in the one‐step method for pooling study results
Greenland, S., & Salvan, A. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090307 · Cited by 165
Low-density lipoproteins and risk for coronary artery disease
Ballantyne, C. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00769-3 · Cited by 147
Management of Barrett's oesophagus
Kelley, D. J., & Shah, J. P. (1996) · The Lancet · doi:10.1016/s0140-6736(05)64794-0 · Cited by 110
Antithrombotic Agents in Coronary Artery Disease
Cairns, J. A., Lewis, H. D., Meade, T. W., Sutton, G. C., & Théroux, P. (1995) · CHEST Journal · doi:10.1378/chest.108.4_supplement.380s · Cited by 50
Rao, A. K., Sun, L., Chesebro, J. H., Fuster, V., Harrington, R. A., Schwartz, D., Gallo, P. P., Matos, D., & Topol, E. J. (1996) · Circulation · doi:10.1161/01.cir.94.10.2389 · Cited by 41
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Self-citationAntman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citation
Metadata
- Authors
- Antman, E. M., Cohen, M., Radley, D., McCabe, C., Rush, J., Premmereur, J., & Braunwald, E.
- Venue
- Circulation
- Published
- 1999-10-12
- Volume
- 100
- Issue
- 15
- Pages
- 1602-1608
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2091795351
- Cited by
- 476
- References
- 39
- FWCI
- 39.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.